NOSH-aspirin

NOSH-aspirin (NBS-1120) is an orally active hybrid molecule that releases nitric oxide and hydrogen sulfide. NOSH-aspirin inhibits pancreatic cancer cell proliferation and induces apoptosis. NOSH-aspirin inhibits cancer cell growth and suppresses NF-κB and FoxM1 in a mouse model of pancreatic cancer. NOSH-aspirin also alleviates motor deficits and dopaminergic neuron degeneration in a rat model of Parkinson's disease. NOSH-aspirin reduces neuroinflammation caused by microglial and astrocytic activation. NOSH-aspirin can be used in research on cancers such as pancreatic cancer and neurological diseases such as Parkinson's disease[1][2][3].

Product Specifications

CAS Number

[1357362-67-4]

Product Name Alternative

NBS-1120

UNSPSC

12352005

Target

Apoptosis; NF-κB

Related Pathways

Apoptosis; NF-κB

Field of Research

Cancer; Neurological Disease

Smiles

O=C(OC1=CC=C(C(SS2)=CC2=S)C=C1)C3=CC=CC=C3OC(CCCO[N+]([O-])=O)=O

Molecular Formula

C20H15NO7S3

Molecular Weight

477.53

References & Citations

[1]Lee M, et al. NOSH-aspirin (NBS-1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: a new candidate for treatment of neurodegenerative disorders. Glia. 2013 Oct;61 (10) :1724-34.|[2]Chattopadhyay M, et al. NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS. Biochem Pharmacol. 2020 Jun;176:113857. |[3]Firouzan B, et al. NOSH-aspirin (NBS-1120) attenuates motor defects and dopaminergic neuron degeneration in a rat model of Parkinson's disease. Eur J Pharmacol. 2025 Sep 5;1002:177733.